Telephone: 1-301-435-4651; Fax: 1-301-435-4655
Cancer Stem Cells
Article first published online: 30 DEC 2010
Copyright © 2010 AlphaMed Press
Volume 28, Issue 12, pages 2129–2140, December 2010
How to Cite
Abou-Kheir, W. G., Hynes, P. G., Martin, P. L., Pierce, R. and Kelly, K. (2010), Characterizing the Contribution of Stem/Progenitor Cells to Tumorigenesis in the Pten−/−TP53−/− Prostate Cancer Model. STEM CELLS, 28: 2129–2140. doi: 10.1002/stem.538
Author contributions: W.G. A.-K.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; P.G.H.: collection and assembly of data, data analysis and interpretation, manuscript writing; P.L.M.: collection and assembly of data, data analysis and interpretation; R.P.: collection and assembly of data; K.K.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript. P.G.H. and P.L.M. contributed equally to this article.
First published online in STEM CELLS EXPRESS October 8, 2010.
Disclosure of potential conflicts of interest is found at the end of this article.
- Issue published online: 30 DEC 2010
- Article first published online: 30 DEC 2010
- Accepted manuscript online: 8 OCT 2010 02:17PM EST
- Manuscript Accepted: 22 SEP 2010
- Manuscript Received: 5 APR 2010
- Intramural Research Program of the NIH
- National Cancer Institute
- Center for Cancer Research, USA
- Cancer stem cells;
Loss of PTEN is one of the most common mutations in prostate cancer, and loss of wild-type TP53 is associated with prostate cancer progression and castrate resistance. Modeling prostate cancer in the mouse has shown that while Pten deletion in prostate epithelial cells leads to adenocarcinoma, combined loss of Pten and TP53 results in rapidly developing disease with greater tumor burden and early death. TP53 contributes significantly to the regulation of stem cell self-renewal, and we hypothesized that loss of Pten/TP53 would result in measurable changes in prostate cancer stem/progenitor cell properties. Clonogenic assays that isolate progenitor function in primary prostate epithelial cells were used to measure self-renewal, differentiation, and tumorigenic potential. Pten/TP53 null as compared with wild-type protospheres showed increased self-renewal activity and modified lineage commitment. Orthotopic transplantation of Pten/TP53 null cells derived from protospheres produced invasive Prostatic Intraepithelial Neoplasia (PIN)/adenocarcinoma, recapitulating the pathology seen in primary tumors. Pten/TP53 null progenitors relative to wild type also demonstrated increased dependence on the AKT/mammalian target of rapamycin complex 1 (mTORC1) and androgen receptor (AR) pathways for clonogenic and tumorigenic growth. These data demonstrate roles for Pten/TP53 in prostate epithelial stem/progenitor cell function, and moreover, as seen in patients with castrate-resistant prostate cancer, suggest for the involvement of an AR-dependent axis in the clonogenic expansion of prostate cancer stem cells. STEM CELLS 2010;28:2129–2140